Novo Nordisk's share price is down 40% year todate and a huge 60% in 2024. It has built a formidable moat around its GLP-1 therapies - notably Ozempic and Wegovy.
While Novo Nordisk is not quite in the "cigar butt" territory, I believe that it is undervalued and oversold. Novo Nordisk also pays a good dividend at 3.30% yield and has solid fundamentals, great for dividend seeking investors like me.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- okcoΒ·2025-08-18TOP1111Report
- zumaΒ·2025-08-17thx1Report
- δΈζ»ιΈ.Β·2025-08-16θ°’θ°’εδΊ«1Report